Ken Zeidner, Ph.D., Esq.
Ken is an accomplished attorney with 20 years of experience in patent preparation and prosecution, patent strategy and litigation, and client counseling, with a particularly strong background in biotechnology and pharmaceutical patent and regulatory law. He obtained his law degree from Benjamin N. Cardozo School of Law, graduating summa cum laude. In addition, he received a Ph.D. in medical and molecular genetics from Mount Sinai School of Medicine, where his doctoral research provided preclinical data for FDA approval of enzyme replacement therapy for Fabry disease. Prior to joining Pergament & Cepeda, Ken was most recently VP of Global Intellectual Property Portfolio and Strategy at Amneal Pharmaceuticals. He is licensed to practice in New York and New Jersey and before the United States Supreme Court, the United States Court of Appeals for the Federal Circuit and the United States Patent & Trademark Office.
